I forhold til placebo nedsatte Fablyn signifikant totalkolesterol, LDL- kolesterol, LDL- associeret apolipoprotein B- 100 og high- sensitivity C- reaktivt protein (gennemsnitlige ændringer henholdsvis - 10, 4%, - 15, 8%, - 11, 8%, - 12, 5%); Der blev ikke set signifikante ændringer af HDL- kolesterol eller VLDL- kolesterol.
Relative to placebo, FABLYN significantly decreased total cholesterol, LDL cholesterol, LDL-associated apolipoprotein B-100, and high sensitivity C-reactive protein (median changes -10.4%, -15.8%, -11.8%, -12.5%, respectively); no significant changes versus placebo were seen for HDL cholesterol or VLDL cholesterol.